Article
Neurosciences
Derek Wong, Tae Hoon Lee, Amy Lum, Valerie Lan Tao, Stephen Yip
Summary: In this study, the transcriptomic and proteomic profiles of low-grade gliomas (LGG) were investigated using RNA-seq data and tandem mass-spectrometry analysis. The results showed that gene expression in LGG subtypes was mainly influenced by IDH mutations and 1p19q co-deletion. Proteomic analysis identified subtype-specific proteins that could be used to classify the LGG subtypes.
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2022)
Article
Oncology
Rachel J. Keogh, Razia Aslam, Maeve A. Hennessy, Zac Coyne, Bryan T. Hennessy, Oscar S. Breathnach, Liam Grogan, Patrick G. Morris
Summary: This retrospective study at a National Neuro-Oncology center investigated the tolerability of PCV chemotherapy in routine clinical practice and found that few patients could complete all 6 cycles of treatment with common hematological toxicities observed. It may be preferable to adjust chemotherapy doses from the start or consider alternative treatment, especially in older patients with LGG.
Article
Pathology
Sakun Santisukwongchote, Chinnachote Teerapakpinyo, Piyamai Chankate, Piti Techavichit, Atthaporn Boongird, Sith Sathornsumetee, Samasuk Thammachantha, Pornsuk Cheunsuchon, Jantima Tanboon, Paul Scott Thorner, Shanop Shuangshoti
Summary: This study successfully achieved integrated diagnosis of diffuse gliomas in adult Thai patients using a simplified approach combining clinical, morphological, immunohistochemical, and fewer molecular tests, saving 50% of testing costs. The demographic data and tumor subtypes were similar to series from other regions of the world.
PATHOLOGY RESEARCH AND PRACTICE
(2021)
Article
Oncology
Stephen Ahn, Young Kim, Ja Shin, Jae-Sung Park, Changyoung Yoo, Youn Lee, Yong-Kil Hong, Sin-Soo Jeun, Seung Yang
Summary: Modified procarbazine and lomustine chemotherapy is a viable alternative for recurrent glioma with reduced toxicity and comparable clinical efficacy.
Article
Radiology, Nuclear Medicine & Medical Imaging
Laura Mancini, Stefano Casagranda, Guillaume Gautier, Philippe Peter, Bruno Lopez, Lewis Thorne, Andrew McEvoy, Anna Miserocchi, George Samandouras, Neil Kitchen, Sebastian Brandner, Enrico De Vita, Francisco Torrealdea, Marilena Rega, Benjamin Schmitt, Patrick Liebig, Eser Sanverdi, Xavier Golay, Sotirios Bisdas
Summary: This study investigated the clinical value of different CEST metrics for glioma classification and found that CEST-derived biomarkers for amides, amines, and their ratio are useful for histomolecular staging in gliomas. The study also revealed that AB/FS CEST mismatch can identify glioma subgroups that may have prognostic and clinical relevance.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Review
Radiology, Nuclear Medicine & Medical Imaging
Simin Zhang, Lijuan Yin, Lu Ma, Huaiqiang Sun
Summary: This study systematically reviewed the literature on the use of artificial intelligence methods in magnetic resonance imaging (MRI) for predicting 1p/19q co-deletion status in glioma. The findings suggest that integrating MRI with AI technology can help determine 1p/19q status pre-operatively and noninvasively, aiding in clinical decision-making. However, further validation and improvement are needed before this approach can be considered reliable and feasible in a real clinical setting.
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2023)
Article
Oncology
Kurt A. Jaeckle, Karla Ballman, Martin van den Bent, Caterina Giannini, Evanthia Galanis, Paul D. Brown, Robert B. Jenkins, J. Gregory Cairncross, Wolfgang Wick, Michael Weller, Kenneth D. Aldape, Jesse G. Dixon, S. Keith Anderson, Jane H. Cerhan, Jeffrey S. Wefel, Martin Klein, Stuart A. Grossman, David Schiff, Jeffrey J. Raizer, Frederick Dhermain, Donald G. Nordstrom, Patrick J. Flynn, Michael A. Vogelbaum
Summary: The study demonstrated that patients treated with temozolomide alone had significantly shorter progression-free survival (PFS) compared to those receiving radiotherapy. Patients not receiving radiotherapy also had shorter PFS, but there was no significant difference in overall survival. There were no significant differences between groups in terms of adverse events and neurocognitive decline.
Article
Oncology
Yanyu Zhang, Yuan Xie, Liqun He, Jiefu Tang, Qiyuan He, Qingze Cao, Langjun Cui, Wei Guo, Kai Hua, Anna Dimberg, Liang Wang, Lei Zhang
Summary: This study found that in IDH-mutated LGGs, most TAMs expressed M1 activation markers CD86 and TNF, with some TAMs co-expressing both M1 and M2-related markers. Higher levels of TAMs expressing M2-related markers were observed in 1p/19q non-codeletion IDH-mutated LGGs compared to 1p/19q codeletion LGGs. Inhibition of M-CSF and TGF beta 1 signaling decreased tumor growth and modulated TAM phenotype in a glioma mouse model, indicating a potential role of these proteins in regulating TAM phenotype in glioma.
Article
Oncology
Shingo Kihira, Ahrya Derakhshani, Michael Leung, Keon Mahmoudi, Adam Bauer, Haoyue Zhang, Jennifer Polson, Corey Arnold, Nadejda M. Tsankova, Adilia Hormigo, Banafsheh Salehi, Nancy Pham, Benjamin M. Ellingson, Timothy F. Cloughesy, Kambiz Nael
Summary: This study developed a multi-parametric radiomic model using MRI to predict the 1p/19q co-deletion status in patients with newly diagnosed IDH1 mutant glioma. The model demonstrated improved diagnostic performance compared to the T2-FLAIR mismatch sign in determining the 1p/19q co-deletion status.
Article
Oncology
Jad Zreik, Panagiotis Kerezoudis, Mohammed Ali Alvi, Yagiz U. Yolcu, Sani H. Kizilbash
Summary: Despite the inclusion of 1p/19q codeletion as a required diagnostic component for oligodendrogliomas in the 2016 WHO classification, study findings revealed persistent regional disparities in reported testing and identified new disparities in race/ethnicity that may impact patient management. Patients who underwent reported testing were more likely to receive adjuvant treatment, highlighting the importance of comprehensive testing for better treatment outcomes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Julia Gilhodes, Adele Meola, Bastien Cabarrou, Guillaume Peyraga, Caroline Dehais, Dominique Figarella-Branger, Francois Ducray, Claude-Alain Maurage, Delphine Loussouarn, Emmanuelle Uro-Coste, Elizabeth Cohen-Jonathan Moyal, POLA Network
Summary: Since the WHO's classification of primary brain tumors in 2016, oligodendrogliomas with the 1p/19q codeletion have been identified as having a better prognosis. However, the response to treatment for these tumors remains heterogeneous. Our study identified a gene signature composed of eight genes that were associated with a poor response to treatment in 1p/19q codeleted tumors. This signature could be used to identify patients who require more intensive treatment.
Article
Clinical Neurology
Ahmet Kursat Karaman, Bora Korkmazer, Nil Urganci, Guelcin Bas, Serdar Arslan, Nil Comunoglu, Mehmet Murat Hanci, Osman Kizilkilic
Summary: This case report describes a rare case of oligodendroglioma with spinal drop metastases, which is the first molecularly-defined spinal metastatic oligodendroglioma. Oligodendroglioma patients with spinal cord-related symptoms should be aware of the possibility of drop metastases. Currently, there is no standard approach for the diagnosis and treatment of spinal metastases of this type of glial tumor.
FRONTIERS IN NEUROLOGY
(2022)
Article
Oncology
Mythili Merchant, Margarita Raygada, Ying Pang, Martha Quezado, Mark Raffeld, Liqiang Xi, Jung Kim, Manoj Tyagi, Zied Abdullaev, Olga Kim, Zach Sergi, Tina Pillai, Byram Ozer, Kareem Zaghloul, John D. Heiss, Terri S. Armstrong, Mark R. Gilbert, Kenneth Aldape, Jing Wu
Summary: Most tumors, including brain tumors, occur sporadically. However, there is a small subset of central nervous system tumors that are associated with Lynch Syndrome. This report presents a rare case of an oligodendroglioma with a PMS2 mutation associated with Lynch Syndrome. The limited literature on germline PMS2 mutations and oligodendrogliomas highlights the importance of genetic testing in neuro-oncology.
FRONTIERS IN ONCOLOGY
(2022)
Article
Clinical Neurology
Ines Esparragosa Vazquez, Mane Ndiaye, Anna Luisa Di Stefano, Nadia Younan, Delphine Larrieu-Ciron, Antoine Seyve, Thiebaud Picart, David Meyronet, Claire Boutet, Francois Vassal, Catherine Carpentier, Dominique Figarella-Branger, Caroline Dehais, Fabien Forest, Romain Rivoirard, Francois Ducray
Summary: This study describes the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with PCV chemotherapy alone. The MRI modifications around the surgical cavity can wrongly suggest tumor progression, and multimodal imaging and close follow-up should be considered in this situation.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Pathology
Aparna Pallavajjala, Lisa Haley, Victoria Stinnett, Emily Adams, Roshni Pallavajjala, Jialing Huang, Laura Morsberger, Melanie Hardy, Patty Long, Christopher D. Gocke, James R. Eshleman, Fausto J. Rodriguez, Ying S. Zou
Summary: Molecular classification of brain neoplasms is crucial for diagnosis, prognosis, and treatment outcomes. This proof-of-concept study demonstrated the feasibility of using targeted next-generation sequencing (NGS) to simultaneously detect 1p/19q co-deletion and somatic mutations, providing a more comprehensive genetic profiling for glioma patients.
Article
Oncology
Antonio Omuro, Alba A. Brandes, Antoine F. Carpentier, Ahmed Idbaih, David A. Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bahr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z. Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller
Summary: This study showed that TMZ + RT had better efficacy than NIVO + RT in newly diagnosed GBM patients with unmethylated MGMT promoter. However, no new safety signals were detected with NIVO in this study.
Article
Oncology
Emilie Le Rhun, Felix Boakye Oppong, Martin van den Bent, Wolfgang Wick, Alba A. Brandes, Martin J. B. Taphoorn, Michael Platten, Ahmed Idbaih, Paul M. Clement, Matthias Preusser, Vassilis Golfinopoulos, Thierry Gorlia, Michael Weller
Summary: This study retrospectively analyzed the incidence of lomustine-induced thrombocytopenia and its impact on treatment exposure and survival in patients with recurrent glioblastoma. The results showed that thrombocytopenia induced by lomustine is a major limitation to adequate exposure to lomustine chemotherapy and is associated with inferior progression-free survival, particularly in patients with MGMT promoter-methylated tumors.
EUROPEAN JOURNAL OF CANCER
(2023)
Letter
Oncology
Mei-Yin C. Polley, Thierry Gorlia, Andy B. Lassman, Martin J. van den Bent
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
I. Hernandez-Verdin, E. Kirasic, K. Wienand, K. Mokhtari, S. Eimer, H. Loiseau, A. Rousseau, J. Paillassa, G. Ahle, F. Lerintiu, E. Uro-Coste, L. Oberic, D. Figarella-Branger, O. Chinot, G. Gauchotte, L. Taillandier, J. -P. Marolleau, M. Polivka, C. Adam, R. Ursu, A. Schmitt, N. Barillot, L. Nichelli, F. Lozano-Sanchez, M. -J. Ibanez-Julia, M. Peyre, B. Mathon, Y. Abada, F. Charlotte, F. Davi, C. Stewart, A. de Reynies, S. Choquet, C. Soussain, C. Houillier, B. Chapuy, K. Hoang-Xuan, A. Alenorn
Summary: Through comprehensive multi-omic analysis, we identified and characterized four molecular patterns in PCNSL, which have a distinct prognostic impact and can guide future clinical stratification and targeted interventions.
ANNALS OF ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Sebastien Durand, Marion Bruelle, Fleur Bourdelais, Bigitha Bennychen, Juliana Blin-Gonthier, Caroline Isaac, Aurelia Huyghe, Sylvie Martel, Antoine Seyve, Christophe Vanbelle, Annie Adrait, Yohann Coute, David Meyronet, Frederic Catez, Jean-Jacques Diaz, Fabrice Lavial, Emiliano P. Ricci, Francois Ducray, Mathieu Gabut
Summary: The study reveals that RSL24D1 is highly expressed in both mouse and human pluripotent stem cells and is involved in the biogenesis of 60S subunits. Depletion of RSL24D1 impairs global translation, particularly of pluripotency factors and components from the Polycomb Repressive Complex 2 (PRC2), leading to altered self-renewal and lineage commitment choices in embryonic stem cells.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Philipp Karschnia, Antonio Dono, Jacob S. Young, Stephanie T. Juenger, Nico Teske, Levin Haeni, Tommaso Sciortino, Christine Y. Mau, Francesco Bruno, Luis Nunez, Ramin A. Morshed, Alexander F. Haddad, Michael Weller, Martin van den Bent, Juergen Beck, Shawn Hervey-Jumper, Annette M. Molinaro, Nitin Tandon, Roberta Ruda, Michael A. Vogelbaum, Lorenzo Bello, Oliver Schnell, Stefan J. Grau, Susan M. Chang, Mitchel S. Berger, Yoshua Esquenazi, Joerg-Christian Tonn
Summary: This study retrospectively analyzed 681 patients with first recurrence of IDH wild-type glioblastomas. It found that re-resection could prolong the survival time of patients, and residual contrast-enhancing tumor of 1 cm³ or less had longer survival than non-surgical management. Complete resection according to the RANO resect classification had a better prognosis. Patients without postoperative deficits who received (radio-)chemotherapy had enhanced survival associations with smaller residual contrast-enhancing tumors. However, resection of non-contrast-enhancing tumor did not prolong survival.
Article
Oncology
Michael Weller, Emilie Le Rhun, Martin Van den Bent, Susan M. Chang, Timothy F. Cloughesy, Roland Goldbrunner, Yong-Kil Hong, Rakesh Jalali, Michael D. Jenkinson, Giuseppe Minniti, Motoo Nagane, Evangelia Razis, Patrick Roth, Roberta Ruda, Ghazaleh Tabatabai, Patrick Y. Wen, Susan C. Short, Matthias Preusser
Summary: The European Association of Neuro-Oncology (EANO) has developed recommendations for the prevention, diagnosis, and management of adverse effects and complications in adult primary brain central nervous system (CNS) tumor patients. The recommendations cover surgery, radiotherapy, and pharmacotherapy, including dose adaptations, interruptions, and reexposure, and summarize unnecessary, inactive, or contraindicated interventions. This consensus paper serves as a reference for standard therapy in clinical trials and clinical practice.
Review
Oncology
Felix Sahm, Sebastian Brandner, Luca Bertero, David Capper, Pim J. French, Dominique Figarella-Branger, Felice Giangaspero, Christine Haberler, Monika E. Hegi, Bjarne W. Kristensen, Kathreena M. Kurian, Matthias Preusser, Bastiaan B. J. Tops, Martin van den Bent, Wolfgang Wick, Guido Reifenberger, Pieter Wesseling
Summary: In the 5th edition of the WHO CNS tumor classification, molecular characteristics have become important diagnostic criteria for many CNS tumor types. This guideline focuses on the methods used for diagnosing gliomas, glioneuronal, and neuronal tumors using informative molecular markers. Various molecular methods are discussed, including next-generation sequencing, methylation profiling, and immunohistochemistry. The guideline also covers the analysis of MGMT promoter methylation status, and provides an overview of the advantages, limitations, and requirements of different assays. The importance of molecular diagnostic testing in neuro-oncology is emphasized, along with discussions on clinical relevance, accessibility, cost, and ethical aspects.
Article
Hematology
Daniel P. Noij, Martin van den Bent, Jeanette K. Doorduijn, Nick Wlazlo
Summary: We report a case of a 19-year-old patient who experienced two episodes of donor-derived PCNSL after undergoing allogeneic stem cell transplantation in childhood. Despite failed induction chemotherapy, successful consolidation therapy was achieved through a second allogeneic stem cell transplantation after conditioning with thiotepa, busulfan, and fludarabine.
ACTA HAEMATOLOGICA
(2023)
Article
Clinical Neurology
Sybren L. N. Maas, Philipp Sievers, Damien C. Weber, Michael Weller, Martin J. van den Bent, Maximilian J. Mair, Johan M. Kros, Fransesca Carparrotti, Andreas von Deimling, Villa Freixa Salvador, Saskia Marguerite Peerdeman, Jose Casas-Martin, Thierry Gorlia, Felix Sahm, Matthias Preusser
ACTA NEUROPATHOLOGICA
(2023)
Article
Oncology
Ioannis Ntafoulis, Anne Kleijn, Jie Ju, Kevin Jimenez-Cowell, Federica Fabro, Michelle Klein, Romain Tching Chi Yen, Rutger K. Balvers, Yunlei Li, Andrew P. Stubbs, Trisha V. Kers, Johan M. Kros, Sean E. Lawler, Laurens V. Beerepoot, Andreas Kremer, Ahmed Idbaih, Maite Verreault, Annette T. Byrne, Alice C. O'Farrell, Kate Connor, Archita Biswas, Manuela Salvucci, Jochen H. M. Prehn, Diether Lambrechts, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Martin J. van den Bent, Clemens M. F. Dirven, Sieger Leenstra, Martine L. M. Lamfers
Summary: This study found that patient-derived glioma stem-like cells (GSCs) retain patient-unique gene expressions despite the loss of their natural environment. Drug screening using GSCs predicted patient response to temozolomide (TMZ) more specifically than the MGMT status alone. Transcriptome analysis identified potential biomarkers for TMZ sensitivity.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Tobias Kessler, Daniel Schrimpf, Laura Doerner, Ling Hai, Leon D. Kaulen, Jakob Ito, Martin van den Bent, Martin Taphoorn, Alba A. Brandes, Ahmed Idbaih, Julien Domont, Paul M. Clement, Mario Campone, Martin Bendszus, Andreas von Deimling, Felix Sahm, Michael Platten, Wolfgang Wick, Antje Wick
Summary: The EORTC-26101 study investigated the efficacy of combination therapy with bevacizumab and lomustine versus lomustine alone in progressive glioblastoma. Molecular data from DNA methylation arrays and panel sequencing were analyzed to assess prognostic biomarkers. The study found that MGMT promoter methylation and RTK1 classifier assignment were prognostic factors, while NF1 mutation may predict response to bevacizumab treatment.
CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Oncology
Patrick Y. Wen, Martin van den Bent, Michael A. Vogelbaum, Susan M. Chang
Article
Oncology
Philipp Karschnia, Jorg Dietrich, Francesco Bruno, Antonio Dono, Stephanie T. Juenger, Nico Teske, Jacob S. Young, Tommaso Sciortino, Levin Haeni, Martin van den Bent, Michael Weller, Michael A. Vogelbaum, Ramin A. Morshed, Alexander F. Haddad, Annette M. Molinaro, Nitin Tandon, Juergen Beck, Oliver Schnell, Lorenzo Bello, Shawn Hervey-Jumper, Niklas Thon, Stefan J. Grau, Yoshua Esquenazi, Roberta Ruda, Susan M. Chang, Mitchel S. Berger, Daniel P. Cahill, Joerg-Christian Tonn
Summary: The absence of contrast enhancement in glioblastomas characterizes a less aggressive clinical phenotype, with smaller postoperative tumor volumes associated with more favorable outcomes. Maximal resection of non-CE tumors has prognostic implications and leads to a better outcome compared to lesion biopsy. Patients with non-CE glioblastoma have a more favorable clinical profile and superior outcome when compared to those with CE glioblastoma.
Review
Oncology
Marta Maccari, Chooyoung Baek, Mario Caccese, Susanna Mandruzzato, Alba Fiorentino, Valeria Interno, Alberto Bosio, Giulia Cerretti, Marta Padovan, Ahmed Idbaih, Giuseppe Lombardi
Summary: Glioblastoma (GBM) is a common and aggressive brain tumor with poor treatment outcomes. Standard therapies have not been effective, leading to a growing interest in immunotherapic approaches. However, GBM is highly immunosuppressive, which may explain the failures of immunotherapy clinical trials. This review examines the current landscape of immunotherapy strategies in GBM, focusing on the challenge of immunoresistance and potential mechanisms to overcome it.
